Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Great. Thank you for joining us. I'm Maxwell Skor, biotech analyst with Morgan Stanley and before we get started, I need to read an important disclosure. Please note that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures.
Great. Now, I'd like to welcome Randy Schatzman, CEO of Bolt Biotherapeutics. For those of us who are either new or revisiting the Bolt story, I think it would be great if we can talk about a high-level discussion of the platform followed by the lead asset, BDC-1001, and then future directions.
Yeah. I'd be happy to do that. Thanks for having us, Max. Good to be with you today.
Questions & Answers
Thank you.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |